In its first move towards fulfilling the president's campaign promise to reduce the cost of prescription drugs, the Trump administration released a 28-page document summarizing a number of ways to push down prices.

Most of the suggested policies are traditional right-of-center ideas that emphasize the benefits of competition and the harms of government regulation. Few of the proposed solutions are specific.

The administration points a finger at the FDA, saying that the time it takes the agency to review and approve new drugs leaves consumers with fewer generic options and higher prices. One potential solution, it suggests, is to change "the criteria for expedited review to include new molecular entities that are second or third in a class, or second or third for a given indication for which there are no generics."